Examination of the genetic factors underlying the cognitive variability associated with neurofibromatosis type 1 by Ottenhoff, M.J. (Myrthe) et al.
Examination of the genetic factors underlying the cognitive
variability associated with neurofibromatosis type 1
Myrthe J. Ottenhoff, MD, MSc 1,2,3, André B. Rietman, MSc3,4, Sabine E. Mous, PhD3,4,
Ellen Plasschaert, PhD5, Daniela Gawehns, MSc3,4, Hilde Brems, PhD5,
Rianne Oostenbrink, MD, PhD2,3, ENCORE-NF1 Team, Rick van Minkelen, PhD6, Mark Nellist, PhD6,
Elizabeth Schorry, MD7, Eric Legius, MD, PhD5, Henriette A. Moll, MD, PhD2,3 and
Ype Elgersma, PhD 1,3
Purpose: Neurofibromatosis type 1 (NF1) is an autosomal
dominant disorder associated with cognitive deficits. The NF1
cognitive phenotype is generally considered to be highly variable,
possibly due to the observed T2-weighted hyperintensities, loss of
heterozygosity, NF1-specific genetic modifiers, or allelic imbalance.
Methods: We investigated cognitive variability and assessed the
contribution of genetic factors by performing a retrospective cohort
study and a monozygotic twin case series. We included data of 497
children with genetically confirmed NF1 and an IQ assessment,
including 12 monozygotic twin and 17 sibling sets.
Results: Individuals carrying an NF1 chromosomal microdeletion
showed significant lower full-scale IQ (FSIQ) scores than
individuals carrying intragenic pathogenic NF1 variants. For the
intragenic subgroup, the variability in cognitive ability and the
correlation of IQ between monozygotic NF1 twin pairs or between
NF1 siblings is similar to the general population.
Conclusions: The variance and heritability of IQ in individuals
with NF1 are similar to that of the general population, and hence
mostly driven by genetic background differences. The only factor
that significantly attenuates IQ in NF1 individuals is the NF1
chromosomal microdeletion genotype. Implications for clinical
management are that individuals with intragenic NF1 variants that
score <1.5–2 SD below the mean of the NF1 population should be
screened for additional causes of cognitive disability.
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INTRODUCTION
Neurofibromatosis type 1 (NF1, OMIM 162200) is a genetic
disorder (birth prevalence ~1:2000)1 caused by heterozygous
loss-of-function variants in NF1 (OMIM 613113). NF1
encodes the protein neurofibromin, which is a negative
regulator of the RAS signaling pathway. Hallmark NF1
features are café-au-lait spots, inguinal freckling, (sub)
cutaneous neurofibromas, plexiform neurofibromas, hamarto-
mas of the iris, optic pathway gliomas, and bone dysplasia.2 In
addition to these somatic features, NF1 individuals have
cognitive deficits, behavioral problems, and motor difficul-
ties.3,4 The cognitive deficits significantly impact the daily lives
of NF1 individuals, as cognitive deficits are rated the highest
disease burden in childhood.5–7 Additionally, the prevalence of
attention deficit–hyperactivity disorder and autism spectrum
disorder is increased tenfold in the NF1 population.5,8,9
NF1 is inherited in a Mendelian manner with complete
penetrance. Nonetheless, individual NF1 characteristics are
highly variable in severity and occurrence. Family studies
confirmed this phenotypic variability for somatic character-
istics such as café-au-lait spots, optic pathway glioma, and
various types of neurofibromas by showing low heritability
among first and second degree affected family members10,11
and even monozygotic (MZ) twins.12,13 These findings suggest
that a noninherited mechanism drives the etiology of somatic
disease characteristics. Indeed, genetic and molecular studies
reveal somatic second-hit variants in the unaffected NF1 allele
(leading to loss of heterozygosity [LOH]) in many NF1-
related lesions.14
The cognitive phenotype is assumed to be highly variable as
well, which has led researchers to propose several mechanisms
that could cause this variability. This includes mechanisms that
are determined by one’s genetic makeup, such as specific effects
of certain pathogenic NF1 variants (genotype–phenotype
effects)15 or variants in other genes that either worsen or
ameliorate the effect of the pathogenic NF1 variant (genetic
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modifiers).15,16 Additionally, mechanisms that are noninherited
and individual-specific, such as LOH15 and the presence of T2-
weighted hyperintensities (T2Hs; lesions often found on
magnetic resonance images [MRIs] of the brains of NF1
individuals), could contribute to the variation.17,18 Lastly, it has
been proposed that allelic imbalance could play a role,19–21
which could involve inherited or noninherited mechanisms.22
A known genotype–phenotype correlation has been reported
for individuals who carry large deleletions of NF1 that also
affect neighboring genes (so-called chromosomal microdele-
tions [CMDs]), which results in reduced cognitive ability.23,24
However, since patients with a CMD represent only a small
portion of the NF1 patient population, it cannot explain the
presumed variability of the cognitive phenotype. The relation
between intragenic genotypes and cognitive ability has only
been investigated in terms of the presence of learning problems
as a dichotomous outcome, with one study suggesting a lower
cognitive ability in NF1 individuals with pathogenic splicing
variants relative to the general NF1 population25 and other
studies collectively suggesting a higher cognitive ability for
individuals carrying a specific pathogenic small in-frame
deletion (p.Met992del).26–29
Although several mechanisms have been put forward to
explain the cognitive variability in NF1, it is notable that
clinical studies specifically addressing the extent of the
cognitive variability are lacking. A few family studies did
include a dichotomous variable for learning problems and
showed significant familial clustering.10–12,30 However, the
measurement as well as the power of that study are
insufficient to reliably estimate variability, and the data could
be supportive of either normal cognitive variability or high
variability due to a dominant role of genotype–phenotype
correlations. Hence, we characterized the variability of
cognitive ability in one large cohort of children with NF1
from two independent tertiary referral centers for NF1, and
analyzed the effects of different types of pathogenic NF1
variants. Additionally, we assessed variability of IQ within
NF1 MZ twin pairs and NF1 sibling sets to further quantify
the contribution of noninherited factors and genetic back-
ground to cognitive ability in NF1. We chose full-scale IQ
(FSIQ) as the primary outcome, as it is highly standardized to
yield a normal distribution with a specific mean (100) and
standard deviation (15) in the general population, allowing us
to place our findings in the context of the variability of IQ in
the general population.
MATERIALS AND METHODS
For the retrospective cohort study, we collected data from
patients at two NF1 tertiary referral centers (the Erasmus
Medical Center [EMC] Rotterdam, the Netherlands, and the
University Hospital Leuven [UHL] Belgium) who had
undergone an IQ assessment. Such an assessment is part of
the standard follow-up procedure for all NF1 children visiting
the expertise centers at EMC and UHL. Although we
encourage all children with NF1 in the Netherlands and
Belgium to visit our centers, it is possible that a minority of
the participants visited our center because of behavioral or
cognitive issues, or because they were interested in participat-
ing in one of the clinical trials that were performed in our
centers31,32 or the ongoing trial (clinicaltrials.gov:
NCT02256124). All patients were born between 1990 and
2013, had visited the NF1 outpatient clinic at least once before
January 2018, and had completed IQ testing before the age of
18 (total n= 615). Patients were excluded if (1) a genetic (n=
97) or (2) clinical NF1 diagnosis (according to the National
Institutes of Health [NIH] diagnostic criteria for NF19) was
missing or incomplete (n= 10), (3) individuals had segmental
NF1 (n= 8), (4) a genetically confirmed Legius syndrome was
diagnosed (n= 3), or (5) a concurrent genetic diagnosis other
than NF1 was present affecting cognition or behavior, in
case this was documented in the individual’s medical record
(n= 0). Data on the most recent assessment of FSIQ (primary
outcome), verbal and performance IQ (VIQ, PIQ; secondary
outcomes) were collected. IQs were assessed by a licensed
psychologist as part of a standardized cognitive and
behavioral testing battery using an age-appropriate Wechsler
Intelligence Scale.
For the MZ twin case series, we screened the NF1 patient
registry of the EMC for MZ twin pairs with a genetically
confirmed clinical NF1 diagnosis, and no symptomatic brain
pathology. Eight of nine pairs at the EMC gave consent for IQ
assessment for the purpose of prospective data collection. In
addition, retrospective data from four MZ NF1 twin pairs
from UHL and Cincinnati Children’s Hospital Medical Center
(CCHMC) were included. Like the EMC and UHL, the
CCHMC is also a tertiary referral center for NF1 individuals.
All twin pairs were confirmed to be MZ with an identifier test
(AmpFlSTR Identifiler PCR Amplification Kit, ThermoFisher
Scientific) and their IQs were assessed using an age-
appropriate Wechsler scale. The study was initially designed
to include 29 NF1 MZ twin pairs in order to have enough
power (α= 0.05, β= 0.80) to acknowledge an FSIQ intraclass
correlation (rICC) of 0.615 as significantly lower than that of
MZ twins in the general population (rICC= 0.85).
33 We chose
this decrease in rICC for the power analysis, as it is close to the
rICC for dizygotic twins (0.60),
33 and therefore indicates a
meaningful decrease. We went slightly above this level to
inflate the sample size. However, after including 12 twin pairs
we were prompted to stop further inclusion, as the rICC 95%
confidence interval (CI) excluded the hypothesized rICC of
0.615. Data on VIQ and PIQ were missing for some
retrospective twin cases; therefore, only FSIQ was assessed
for the twin case series. Data collection for the retrospective
data collection for the cohort study and twin case series was
performed with the approval of the EMC Medical Ethics
Review Committee, the Ethics Committee Research UZ/KU
Leuven, and the CCHMC Institutional Review Board.
Additionally, the EMC Medical Ethics Review Committee
approved prospective data collection for the twin case series.
Written informed consent was obtained from all participants
(and from both parents in case of minor participants) who
were recruited for prospective data collection within the twin
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case series. For retrospective data collection, all centers' ethics
committees exempted the study from the requirement of
receiving informed consent from patients. Prospective data
collection for the twin case series was registered in a trial
register (clinicaltrials.gov: NCT02436746).
Molecular NF1 screening and assignment of pathogenicity
was performed in a diagnostic setting. The molecular
techniques used and the method for assigning pathogenicity
have been described previously.11 Pathogenic variants were
classified using the following variant type categories: mis-
sense, frameshift, splicing, nonsense, miscellaneous intragenic
(small [16 amino acids] in-frame insertions and deletions and
large in-frame and out-of-frame insertions and deletions) and
CMDs, including types I–III and atypical deletions. For
intragenic variants, these categories were assigned based on
their predicted coding effect using a visual variant analysis
software package (Alamut Visual, version 2.11). The Leiden
Open Variation Database (LOVD, version 3.0, https://
databases.lovd.nl/shared/genes/NF1) was consulted for each
variant to check if variant-specific RNA-based or protein-
based molecular analyses were published that overruled the in
silico predicted coding effect. It should be noted that such
additional information is only present for a small subset
of variants in LOVD, meaning that it is possible that some
variants have been misclassified (e.g., classified as missense
variants instead of as splicing variants).
Statistical analysis
Shapiro–Wilk tests were performed to determine whether IQ
scores were normally distributed. Linear mixed models
(LMMs) with random center effects that accounted for
within-center nesting were used to assess the effect of
genotype and of variant location along the gene on IQ score.
Main effects of fixed variables in LMMs were tested using
likelihood ratio tests. For these fixed effects, we additionally
calculated standardized effect sizes (f2), for which a value of
≥0.02 is considered small, ≥0.15 medium, and ≥0.35 large.34
Model assumptions for LMMs were checked by visualization
of model residuals (residuals versus fitted values plot for
homoscedasticity and Q–Q plots for normality). Significant
main effects of categorical variables containing >2 levels were
followed up by post hoc testing, which was corrected for
multiple comparisons using the false discovery rate (FDR).
Variance between genotype groups was compared using
Levene’s tests. Intraclass correlations (rICC) of IQ scores
within MZ twin pairs or sibling sets were calculated from a
LMM with FSIQ as the dependent variable, age as fixed effect
and intercepts per twin pair or sibling set as random effects.
We estimated the rICC 95% CIs using 500 bootstrap samples.
Descriptive statistics were obtained with contingency table
analyses or Mann–Whitney U tests depending on variable
type. The significance level was set to α= 0.05 (two-sided).
Statistical analyses were performed using R (v3.5.1, R
foundation), supplemented with the nlme package for LMM
analysis,35 emmeans package for LMM post hoc analysis,36
and gabtools package for extracting r2 values from LMMs for
calculating effect sizes.37
RESULTS
We included 497 children: 394 from the EMC and 103 from
the UHL. The cohorts did not significantly differ in sex
(proportion female: 46% vs. 54%; χ2[1]= 2.00; p= 0.16), age
at IQ assessment (median= 9 [interquartile range, IQR]=
6–12] vs. 8 [6–12]; U= 20,580; p= 0.82), FSIQ (mean= 87.1
[SD= 15.4] vs. 86.6 [14.8]; t[491]=−0.31; p= 0.76) or
variant type (χ2[5]= 8.87; p= 0.11) and were therefore
analyzed together.
To assess if we could confirm a lower cognitive ability for
the CMD genotype, we divided the total cohort over six
different genotype groups: missense (n= 72), frameshift (n=
134), splicing (n= 97), nonsense (n= 129), miscellaneous
intragenic (n= 38), and CMD (n= 25) (Table 1). The main
effect of genotype was significant for all three IQ scores: FSIQ
(likelihood ratio [LR][5]= 27.60; p < 0.001; f2= 0.054), VIQ
(LR[5]= 26.82; p < 0.001; f2= 0.053), and PIQ (LR[5]=
23.62; p < 0.001; f2= 0.046). Subsequent post hoc testing for
FSIQ revealed that the group effect was indeed driven by the
CMD group, which had significantly lower IQ scores
compared with the other groups (Fig. 1 and Table S1).
To assess whether specific intragenic NF1 variants increase
the variability of cognitive ability relative to the general
population, we characterized the variability for all children in
the combined cohort with an intragenic genotype, thus
excluding those with a CMD genotype. The mean FSIQ scores
were lower than expected from the general population,
whereas the SD was similar: mean FSIQ was 87.8 (SD 15.1),
mean VIQ was 90.6 (SD 15.6), and PIQ was 87.9 (SD 15.1).
Visual inspection (Fig. 2) and distribution statistics indicated
a normal distribution for all three IQ scores: FSIQ
(pShapiro–Wilk= 0.17, zskewness=−0.11, zkurtosis=−1.71), VIQ
(pShapiro–Wilk= 0.11, zskewness= 0.55, zkurtosis=−0.67), and
PIQ (pShapiro–Wilk= 0.06, zskewness= 1.77, zkurtosis= 0.50).
When the CMD data were added back into the study sample
(median FSIQ= 87.0 [IQR= 76.0–97.0]; median VIQ= 91.0
[79.5–99.5]; median PIQ= 86.0 [77.0–98.0]), there was a
significant deviation from the normal distribution, in line
with CMD children showing significantly lower IQ scores:









Missense 72 89.3 (15.9) 92.9 (18.2) 89.1 (13.4)
Frameshift 134 88.8 (13.7) 91.6 (13.8) 88.1 (15.1)
Splicing 97 85.7 (16.0) 87.3 (16.4) 87 (16.2)
Nonsense 129 88.0 (14.2) 91.7 (14.4) 87.8 (14.2)
MI 38 85.7 (18.8) 86.8 (17.2) 87.4 (18.4)
CMD 25 72.8 (9.9) 77.4 (10.5) 73.2 (10.9)
CMD chromosomal microdeletion, FSIQ full-scale intelligence quotient, MI mis-
cellaneous intragenic, PIQ performance intelligence quotient, VIQ verbal intelli-
gence quotient.
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FSIQ (pShapiro–Wilk= 0.07, zskewness= 0.28, zkurtosis=−1.98),
VIQ (pShapiro–Wilk= 0.08, zskewness= 0.91, zkurtosis=−0.79),
and PIQ (pShapiro–Wilk= 0.04, zskewness= 1.97, zkurtosis= 0.24).
Additionally, we compared variances between the different
intragenic genotype groups (missense, frameshift, splicing,
nonsense, and miscellaneous intragenic, as defined in
“Materials and Methods.”). These groups did not differ for
FSIQ (F[4463]= 1.95, p= 0.10) and PIQ (F[4465]= 1.15,
p= 0.33), but did for VIQ (F[4465]= 2.75, p= 0.03).
However, FDR-corrected post hoc tests of variances for VIQ
did not yield any significant comparisons between genotype
group pairs (Table S2).
A meta-analysis of MZ twin pair studies in the general
population shows that the correlation of FSIQ between twins
is very high (rICC= 0.85) and is mostly determined by their
genetic makeup.33 If LOH or T2Hs played a significant role in
increasing the variability, this correlation would be expected
to be lower in NF1 MZ twin pairs relative to MZ twins in the
general population, as these factors are considered to
be noninherited, nonshared factors. We, therefore, studied
the correlation of FSIQ within 12 NF1 MZ twin pairs (median
age= 18.5 years [range= 4–27]; 10 female pairs; all reared
together; all had an intragenic NF1 pathogenic variant). The
median FSIQ in this sample was 78 (range= 56–110; lower
quartile= 72; upper quartile= 93). We found a high correla-
tion of FSIQ within pairs (rICC= 0.90 [bootstrapped 95%
CI= 0.71–0.96]) (Fig. 3a), which is similar to the general
adult population (rICC= 0.85).
33 Hence, these results indicate
that the influence of noninherited, nonshared factors such as
LOH is small or nonexistent.
In addition to the twin case series, we performed an
exploratory analysis on 17 sibling sets who we were able to
identify in our retrospective cohort collected from the EMC.
We selected only those sibling sets who had an intragenic NF1
pathogenic variant (15 pairs and 2 sets of three siblings;
median age= 8.5 years [range= 4.0–14.0]; 50.0% female;
none were dizygotic twins). The median FSIQ in this sample
was 85 (range= 55–125; lower quartile= 69; upper quartile
= 94). Within sibling sets, we found a correlation of rICC=
0.52 (bootstrapped 95% CI= 0.19–0.75) (Fig. 3b), which is
close to that of the general population (rICC= 0.46).
33 These
results are in line with the normal distribution and normal
degree of variation of IQ scores found in the intragenic NF1
cohort.
Lastly, as the severity of certain NF1 characteristics is
related to the specific location of a variant along the gene26–29
and one study showed that the severity of autism symptoms
showed a linear relation with variant location along the
gene,38 we performed exploratory analyses on the location-
specific effect of intragenic genotypes. We assumed that
missense variants and small in-frame deletions or insertions
allow expression of neurofibromin, the NF1 gene product
(group P; n= 84), and could possibly be more susceptible to























































Fig. 1 Relationship between neurofibromatosis type 1 (NF1) geno-
type and IQ. Boxplots show the median and interquartile ranges of full-
scale IQ (FSIQ) (a), verbal IQ (VIQ) (b), and performance IQ (PIQ) (c) divided
over the different genotype groups. The horizontal bars and asterisk (*)
indicate comparisons that remain significant after false discovery rate (FDR)-
corrected multiple comparisons. CMD chromosomal microdeletion, MI
miscellaneous intragenic.
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and nonsense variants that are likely to result in absence of
neurofibromin due to nonsense-mediated decay (group X;
n= 262). Because the effects of splice variants on protein
production are often difficult to predict, we excluded these
variants from our analysis. Visual inspection of the relation
between FSIQ and variant location along the gene did not
highlight specific regions, though it did suggest a subtle
positive relation between IQ score and the proximity of the
variant toward the 3'-end of the gene (Fig. 4). However, a
model with fixed effects for variant location, neurofibromin
expression group (P or X), and their interaction explained
very little variation in either IQ score, as it did not provide a
better fit than an intercept-only model for FSIQ (LR[3]=
3.31; p= 0.35; f2= 0.009), VIQ (LR[3]= 4.84; p= 0.18; f2=
0.013), and PIQ (LR[3]= 3.60; p= 0.31; f2= 0.010). More-
over, there was no significant effect of variant location or the
interaction between variant location and neurofibromin
expression group on either of the IQ scores (Table S3). A
previous report showed a relation between variant location
and the severity of autism symptomatology when excluding
variants residing in the GAP-related domain (GRD).38
Therefore, we added GRD location as a variable to our
model. However, this extended model did not show a
significant model fit over an intercept-only model for either
FSIQ (LR[7]= 5.88; p= 0.55; f2= 0.016), VIQ (LR[7]= 6.49;
p= 0.48; f2= 0.017), or PIQ (LR[7]= 5.83; p= 0.56; f2=
0.016), nor a significant effect of GRD location on either FSIQ
(LR[4]= 2.57; p= 0.63; f2= 0.007), VIQ (LR[4]= 1.65; p=
0.80; f2= 0.004), or PIQ (LR[4]= 2.23; p= 0.69; f2= 0.006).
Additionally, there was no significant effect of variant location
or the interaction between variant location and neurofibromin
expression group within this extended model (Table S3).
Together, these nonsignificant effects in the extended model
indicate that the relation between cognitive ability and variant
location is not dependent on the variant residing in the GRD.
DISCUSSION
Here we studied the variability of the cognitive phenotype in
NF1 and explored the extent of several genotype–phenotype
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Fig. 2 Distribution of IQ scores in neurofibromatosis type 1 (NF1) individuals with intragenic genotypes. Density plots and histograms for full-
scale IQ (FSIQ) (a), verbal IQ (VIQ) (b), and performance IQ (PIQ) (c). Solid blue lines and light blue bars show the distribution in NF1 individuals with intragenic
genotypes (no chromosomal microdeletions [CMD]; n= 470). Gray dashed lines are reference normal distributions with the same mean as in the NF1 data
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Fig. 3 Correlation of full-scale IQ (FSIQ) within neurofibromatosis
type 1 (NF1) monozygotic twin pairs. Scatterplots showing the corre-
lation of FSIQ within monozygotic (MZ) NF1 twins (n= 12 pairs) (a) and
sibling sets (n= 17 sets) (b). For the sibling sets that have 3 siblings
(2/17 sets), the two individuals with the highest and lowest FSIQ score are
plotted. The solid lines represent the best linear fit. The different shapes
indicate whether the data were collected at the Erasmus Medical Center
(EMC), Cincinnati Children’s Hospital Medical Center (CCHMC), or Uni-
versity Hospital Leuven (UHL).
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cognitive function in NF1 to date, and the first study relating
a continuous cognitive outcome to different genotypes
observed in NF1 individuals. It is also the first study
quantifying the correlation of a continuous measure of
cognitive function within NF1 MZ twin pairs. While the
mean IQ scores were overall lower than scores in the general
population, and comparable and consistent with IQ scores
found in previous NF1 studies, we found that the variability of
global cognitive functioning in NF1 individuals with an




























































Fig. 4 Relationship between NF1 variant location and IQ. The scatterplot shows the relationship between the location of variants along the gene and
full-scale IQ (FSIQ) (a), verbal IQ (VIQ) (b), and performance IQ (PIQ) (c) for group P (n= 84; missense variants and small in-frame deletions or insertions) and
group X (n= 262; frameshift and nonsense variants) respectively. Long dashed line indicates the IQ mean of the subset of NF1 individuals shown; short
dashed lines indicate its +1 SD and −1 SD. Gray vertical bars represent where known domains are located along the gene, with the darker gray bar
indicating the GRD. The arrows indicate the C-terminal amino acid (corresponding to codon 2818). CSRD cysteine and serine rich domain, GRD GAP-related
domain, SEC14-PH Sec14 homology-like and Pleckstrin homology-like domain, SBD syndecan binding domain, TBD tubulin-binding domain.
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Additionally, we found that the intraclass correlation of IQ
scores within NF1 MZ twin pairs and sibling sets is similar to
correlations found in the general population. Further, we
confirmed that individuals with CMDs have a lower cognitive
ability than individuals with intragenic NF1 pathogenic
variants. We did not identify any genotype–phenotype
correlations within the intragenic variant group, neither
based on variant type, nor on the location of the variant along
the gene.
The normal distribution of IQ scores in children with NF1
in combination with the high correlation of FSIQ within NF1
MZ twins and moderate correlation within NF1 sibling sets
indicates that the variability of the cognitive phenotype in
NF1 individuals is not higher than the unaffected population.
Specifically, the normal distribution and the moderate
correlation within sibling sets suggest that genetic modifiers
have a similar influence on cognition in NF1 individuals as in
the general population.15,16 Furthermore, the high correlation
within NF1 MZ twin pairs suggests that NF1-specific
mechanisms that can be considered to be nonshared
environmental factors do not play a significant role in the
cognitive function of NF1 individuals. These NF1-specific
mechanisms include second-hit variants in the unaffected
NF1 allele, leading to LOH, that are an important driver for
the variability of several somatic NF1 features,14 and may
include T2Hs as seen on brain MRIs. The latter would,
however, be in conflict with a slight majority of studies that
concluded that T2Hs associated with NF1 have a negative
impact cognitive ability.39–42 However, if the presence of
T2Hs shows a high concordance within 11 NF1 MZ twin
pairs as previously suggested,12 it is debatable whether
presence of T2Hs should be considered a nongenetic factor
in the first place. Lastly, while allelic imbalance was observed
in neurons derived from induced pluripotent stem cells of
NF1 individuals and correlated with dopamine signaling,19
our results collectively indicate that allelic imbalance is
unlikely to add significantly to the variability of the cognitive
NF1 phenotype.
We recognize that the sample size of the twin case series
was small. Nonetheless, several factors support the reliability
of the observed rICC for FSIQ. First, we did not observe any
outliers in our data set, identified as being lower than the
lower quartile minus 1.5 times the IQR or higher than the
upper quartile plus 1.5 times the IQR, that could compromise
the accuracy of our found rICCs. The degree of accuracy is also
reflected in the relatively narrow bootstrapped 95% CI.
Second, our participants were rather young, and it is known
that the heritability of IQ in children is smaller than
in adults,43 therefore our estimated rICC is rather conservative.
Additionally, we recognize that the sample size of the sibling
set case series is small. Although the rICC found here (rICC=
0.52) was reasonably close to the rICC of sibling sets in the
general population (rICC= 0.46)
33 and we did not observe any
outliers in this subset either, the 95% CI was (as expected)
much broader than in the twin case series. The sibling rICC
should, therefore, be interpreted with more caution.
The only genotype–phenotype correlation we found con-
firmed that, as a group, children with NF1 with CMD have
lower cognitive abilities.23,24 In line with this finding, we
could show that including individuals with the CMD
genotype in our distribution analysis resulted in a deviation
from the normal distribution. This decreased cognitive ability
in CMD individuals is believed to arise from the codeletion of
genes adjacent to NF1, such as OMG (OMIM 164345) and
RNF135 (OMIM 611358).44 Additionally, we could not find
evidence for other genotype–phenotype correlations among
children with pathogenic intragenic variants: neither for intra-
genic genotype groups nor for gene location-specific geno-
types. Lastly, our results did not show a linear relation
between cognitive ability and the proximity of the variant to
the 3’-end of the gene, as is suggested for autistic traits in NF1
by Morris et al.38 Together with the normal distribution and
variation in our intragenic NF1 cohort and the lack of
significant differences in the variability of IQ scores between
intragenic genotype groups, these findings indicate that if
location-specific genotype–phenotype correlations are to be
identified in the future, they will probably account for a very
small proportion of NF1 individuals.
Nevertheless, intragenic genotype–phenotype correlations
concerning a single or a few neighboring amino acids (i.e.,
p.844–848, p.Met992del, p.Met1149, p.Arg1276, p.Lys1423,
and p.Arg1809) have been identified in the context of
somatic NF1 features.26–29,45 While theoretically one would
only need a sample size of n= 102 for a comparison of these
six specific genotypes alongside a general group with other
missense pathogenic variants (assuming a medium effect size
of f2= 0.15, one categorical fixed effect with four categories,
a significance criterion of α= 0.05, and a power of 1–β=
0.80), one would also need a reasonable number of
individuals per group. As our data included only n= 2
p.844–848, n= 5 p.Met992del, n= 1 p.Met1149, n= 3
p.Arg1276, n= 4 p.Lys1423, and n= 9 p.Arg1809 indivi-
duals, we regarded our data as unsuitable for such an
analysis. Furthermore, our study was not powered to screen
for other genotype–phenotype correlations or to quantify the
explained variation by intragenic genotype–phenotype
correlations with locational specificity at the single amino
acid level. Considering that LOVD reports 152 different
amino acid locations for pathogenic missense NF1 variants
alone, one would need a database with a sample size of at
least n= 462 (f2= 0.15, a significance criterion of α= 0.05,
and a power of 1–β= 0.80) and a reasonable number of
individuals per each of those 152 location categories. This is
very hard to achieve, since a recent study using the largest
NF1 gene variant database to date (8000 individuals) showed
that a combination of the six most common recurrent
missense or in-frame mutational hotspots (i.e., p.844–848,
p.Met992del, p.Met1149, p.Arg1276, p.Lys1423, and
p.Arg1809) represents only 4.8% of unrelated probands.45
There are several clinical implications of our findings. First
of all, we provide a robust confirmation that the chromosomal
microdeletion genotype is associated with a lower cognitive
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ability compared with intragenic NF1 genotypes. Individuals
with intragenic NF1 variants who score >1.5–2 SD below the
NF1 population mean should be screened for additional
variants that may explain the reduced intellectual disability,
similar to current guidelines for the general population.
Additionally, as we observe a downward shift of IQ relative to
the general population, while the variability remains similar,
our findings suggest that cognitive ability is likely to be
similarly affected in all NF1 individuals with an intragenic
genotype, independent of whether their IQ is within the
normal range or not. Hence, for clinical trials that aim to
improve cognitive ability in NF1, inclusion of subjects who
perform in the normal range will likely not attenuate the
treatment effect. Lastly, our data suggest that there is no major
role for NF1-specific genetic or nongenetic modifiers in
determining the severity of the cognitive phenotype of
individuals with NF1. Rather, cognitive ability in NF1 mainly
varies due to normal variation in genetic background as it
does for the general population.
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